
Clinics for Rare Genetic Disorders
Implementing evidence-based exome sequencing for the diagnosis of rare uncharacterized and undiagnosed diseases in low and middle-income countries.
G2MC Functional Groups
G2MC maintains three working groups as well as an ad hoc conference planning working group.
G2MC currently has two flagship projects that are overseen by the Implementation Projects Working Group.
G2MC’s parent organization, the Global Genomic Medicine Collaborative (GGMC), has three core committees that function across all of GGMC’s programs.
Training the next generation of genomic medicine professionals through the development of a mentorship program, educational webinars, and other programs and activities generating leadership skills in the field of genomic medicine.
Analyzing, advocating for, and sharing global policies that support the implementation of genomic medicine.
Fostering a supportive and inclusive environment for genomic medicine professionals from diverse backgrounds and demographics to excel, become leaders within the GGMC organization and its consortia, and be represented across all projects and working groups.
Implementing evidence-based exome sequencing for the diagnosis of rare uncharacterized and undiagnosed diseases in low and middle-income countries.
Promoting the benefits of family health history for patient self-knowledge, family sharing, public screening, pre-screening for genetic testing in a clinical setting, and research.
G2MC was originally made up of three Working Groups: Education, Evidence, and Policy. Each group made significant contributions to G2MC, leading to the success and growth of the organization. In 2022, as part of the G2MC Strategic Planning process and as a result of the organization’s continued growth, these groups were dissolved in order to leverage their contributions at a higher level across the parent organization, the Global Genomic Medicine Collaborative.
The Education Working Group aims to assess and facilitate educational activities to prepare providers in the implementation of genomic medicine in clinical practice worldwide.
The Evidence Working Group aims to monitor evidence of the clinical utility of genomic medicine and to promote awareness about current evidence available to support genomic medicine.
The Policy Working Group seeks to analyze policy issues in the implementation of genomic tools and knowledge into health care delivery.